Exelixis to Present at the William Blair & Co. 37 th Annual Growth Stock
Conference on June 13
-- Presentation to be webcast on
www.exelixis.com --
Exelixis, Inc. (NASDAQ: EXEL) today announced that management will present a corporate overview at the William Blair Growth
Stock Conference taking place June 13-14 in Chicago, IL. The Exelixis presentation is scheduled for 12:30 PM EDT / 11:30 AM local
Chicago time / 9:30 AM PDT on Tuesday, June 13, 2017.
The presentation will be webcast live and may be accessed via the Event Calendar page under Investors & Media at www.exelixis.com. Please connect to the company’s website at least 15 minutes prior to the presentation to
ensure adequate time for any software download that may be required to listen to the webcast. A replay will also be available at
the same location for 14 days.
About Exelixis
Exelixis, Inc. (Nasdaq: EXEL) is a biopharmaceutical company committed to the discovery, development and commercialization of
new medicines to improve care and outcomes for people with cancer. Since its founding in 1994, three products discovered at
Exelixis have progressed through clinical development, received regulatory approval, and entered the marketplace. Two are derived
from cabozantinib, an inhibitor of multiple tyrosine kinases including MET, AXL and VEGF receptors: CABOMETYX™ tablets approved for
previously treated advanced kidney cancer and COMETRIQ® capsules approved for progressive, metastatic medullary thyroid
cancer. The third product, COTELLIC®, is a formulation of cobimetinib, a selective inhibitor of MEK, is marketed under a
collaboration with Genentech (a member of the Roche Group), and is approved as part of a combination regimen to treat advanced
melanoma. Both cabozantinib and cobimetinib have shown potential in a variety of forms of cancer and are the subjects of broad
clinical development programs. For more information on Exelixis, please visit www.exelixis.com or follow @ExelixisInc on Twitter.
Exelixis, the Exelixis logo, COMETRIQ and COTELLIC are registered U.S. trademarks, and CABOMETYX is a U.S.
trademark.
Exelixis, Inc.
Susan Hubbard, 650-837-8194
Executive Vice President,
Public Affairs and
Investor Relations
shubbard@exelixis.com
or
Media Contact:
For Exelixis, Inc.
Hal Mackins, 415-994-0040
hal@torchcommunications.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20170608006270/en/